For example, in breast cancer, PTPN13 was reported to inhibit cancer aggressiveness by Src dephosphorylation [96] which is upregulated in tamoxifen-resistant ER-positive breast cancer patients [97], or DUSP4 repressed expression was identified as a mechanism of neoadjuvant drug chemoresistance and frequently depleted in chemotherapy refractory breast tumours [98]. This evidence concerns the gene PTPN13 and breast neoplasm.